• Virtual Simulcast
  • In-Person
  • Free CME Credits

A Conversation With the Myeloma Experts: Making Sense of the Evolving Treatment Landscape

Join us for this free live symposium featuring discussion of patient case studies and key clinical trial data by renowned clinical experts providing their perspectives on recent advances in the treatment of multiple myeloma.

DATE:
December 9th
TIME:
11AM-1:30PM CT Timezone Converter
LOCATION:
Hyatt Regency New Orleans
601 Loyola Ave
Room: Elite B
New Orleans, LA 70113
SIMULCAST:
11:30AM-1:30PM CT Timezone Converter

Register Now

Agenda

Attend in-person or via virtual simulcast.

DEC 9th: Lunch & Presentation: 11 AM – 2 PM CT
Virtual Simulcast: 11:30 AM – 1:30 PM CT

  • A Conversation With the Myeloma Experts: Making Sense of the Evolving Treatment Landscape 
  • Agenda

    Patient Case Studies with short didactic and panel discussion:
    • How do you determine risk of progression for smoldering MM?
    • When do you consider therapy for patients with smoldering MM?
    • Introduction to the 2023 MM Care Algorithm: Diagnosis
    • What induction therapy is optimal for patients with newly diagnosed MM?
    • What should the ideal duration of therapy be for first-line MM?
    • Introduction to the 2023 MM Care Algorithm: Newly Diagnosed MM
    • When should you start treatment at first relapse?
    • What strategy do you use to select therapy at first relapse?
    • Introduction to the 2023 MM Care Algorithm: Treatment at First Relapse
    • How do you select therapy for an “average” patient who has experienced multiple relapses?
    • Case variation: What patient and disease factors would change your treatment approach?
    • What therapy do you consider for patients after BCMA-targeted treatment?
    • Introduction to the 2023 MM Care Algorithm: Treatment for Heavily Pretreated Disease

Faculty

Brian G.M. Durie, MD

Medical Director, AMyC
Co-Chair Myeloma Committee, SWOG
Chairman, International Myeloma Foundation
Specialist in Multiple Myeloma and Related Disorders
Cedars-Sinai Outpatient Cancer Center
Los Angeles, California

Shaji K. Kumar, MD

Mark and Judy Mullins Professor of Hematological Malignancies
Chair, Myeloma Amyloidosis Dysproteinemia Group
Consultant, Division of Hematology
Mayo Clinic
Rochester, Minnesota

Thomas G. Martin, MD

Clinical Professor of Medicine
Associate Director, Myeloma Program
University of California, San Francisco Medical Center
San Francisco, California

Philippe Moreau, MD

Professor of Clinical Hematology
Head, Hematology Department
University Hospital Hôtel-Dieu
Nantes, France

S. Vincent Rajkumar, MD

Edward W. and Betty Knight Scripps
Professor of Medicine
Mayo Clinic
Rochester, Minnesota

Jesús F. San-Miguel, MD, PhD

Director of Clinical and Translational Medicine
Universidad de Navarra
Pamplona, Spain

Accreditation

JOINT ACCREDITATION INTERPROFESSIONAL CONTINUING EDUCATION

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Disclosure of Conflicts of Interest

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Physician Continuing Medical Education

Designation of Credit

CCO designates this live activity for a maximum of 2.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Location Details

Hyatt Regency New Orleans
601 Loyola Ave
Room: Elite B
New Orleans, LA 70113
Get Directions

Clinical Care Options, LLC. is committed to providing a safe and healthy environment for all our learners. Our decisions and preventive measures are guided by the requirements and recommendations of the CDC alongside federal, state, and local health authorities. We work with each program venue to implement preventive measures to reduce the potential spread of COVID-19. In addition, in accordance with The American Society of Hematology’s (ASH) COVID-19 protocols, all in-person learners will be asked to wear a mask and present their ASH conference badge -OR- proof of vaccination* AND government-issued ID to gain admittance to Acute Lymphoblastic Leukemia Data and Case Discussion on the Use of Asparaginase Therapy in Young and Older Adults.

For more information on ASH’s vaccination and mask requirements, please visit: ASH’S website

*If you do not have your vaccination record card, find other ways to verify you have been vaccinated.

Friday Satellite Symposium on “Advances in the Treatment of T-Cell Lymphomas: A Forum for Data and Case Discussion”, preceding the 64th ASH Annual Meeting and Exposition.

CLINICAL CARE OPTIONS ONCOLOGY logo

Acknowledgements

Provided by Clinical Care Options, LLC, in partnership with the International Myeloma Foundation.

For customer support please email:

[email protected]

Mailing Address Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from

Amgen
Janssen Biotech, Inc. administered by Janssen Scientific Affairs, LLC.
Karyopharm Therapeutics Inc.
Pfizer, Inc.
Regeneron Pharmaceuticals, Inc.
Takeda Pharmaceuticals U.S.A., Inc.